Ulrike Garske-Román

发表

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

M. Lubberink, J. Carlsson, H. Lindman, 2014, The Journal of Nuclear Medicine.

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment

M. Lubberink, H. Lundqvist, A. Sundin, 2013, The Journal of Nuclear Medicine.

Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE

Anders Sundin, Mark Lubberink, Cecilia Wassberg, 2015, The Journal of Nuclear Medicine.

Tracer kinetic analysis of 68Ga-DOTATATE and 68Ga-DOTATOC in neuroendocrine tumours

M. Lubberink, H. Lundqvist, A. Sundin, 2013 .

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

M. Lubberink, H. Lundqvist, A. Sundin, 2014, The Journal of Nuclear Medicine.

: Net Uptake Rate for Accurate Quantification 68 Ga-DOTATOC and 68 Quantitative and Qualitative Intrapatient Comparison of

M. Lubberink, A. Sundin, J. Sörensen, 2014 .

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants

A. Sundin, M. Sandström, Ulrike Garske-Román, 2020, Neuroendocrinology.

Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases

M. Sandström, Ulrike Garske-Román, R. Nyman, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

N. Freedman, A. Sundin, M. Sandström, 2017, Acta oncologica.

Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours Dosimetry-Based Therapy Planning

Ulrike Garske-Román, 2012 .

Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms

Ezgi Ilan, M. Lubberink, A. Sundin, 2021, Cancers.

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors

Ezgi Ilan, M. Lubberink, A. Sundin, 2019, Neuroendocrinology.

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE

A. Sundin, M. Sandström, Ulrike Garske-Román, 2019, Cancers.

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

H. Lundqvist, A. Sundin, M. Sandström, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors

Anders Sundin, Jens Sörensen, Mark Lubberink, 2013, The Journal of Nuclear Medicine.

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

M. Lubberink, A. Sundin, M. Sandström, 2023, EJNMMI Research.

Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours

Ezgi Ilan, N. Freedman, M. Sandström, 2015, EJNMMI Physics.

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

M. Lubberink, J. Carlsson, H. Lindman, 2014, Journal of Nuclear Medicine.